STS-01 for the treatment of alopecia areata

INTERVENTION: Participants are block randomised to be treated with 0.25%, 0.5%, 1.0%, 2% STS‐01 or a matching placebo control topically once daily for 6 months with a 2‐month follow up. CONDITION: Alopecia areata ; Skin and Connective Tissue Diseases ; Alopecia areata PRIMARY OUTCOME: Alopecia areata severity measured using the Severity of Alopecia Tool (SALT) at 0, 2, 4 and 6 months with a 2‐month follow up SECONDARY OUTCOME: ; Measured at 0, 2, 4 and 6 months with a 2‐month follow up; 1. Regrowth area measured by graphical measuring of the size of the patch; 2. AA quality of life measured using Subject Alopecia Areata Symptom Impact Scale (AASIS) and Alopecia Areata Quality of Life Index (AAQLI) 0‐25; 3. Global assessment using the Clinical Global Impression (CGI) score; 4. Cytokines measured using assay of interleukins; INCLUSION CRITERIA: 1. Alopecia areata (<50% SALT score) 2. Not currently receiving treatment for hair loss